BioCentury
ARTICLE | Clinical News

Telcyta: Phase II

June 9, 2003 7:00 AM UTC

Interim results from an ongoing U.S. Phase II trial of Telcyta as monotherapy in stage IV metastatic breast cancer patients showed 1 complete response, 2 partial responses and an overall disease stabi...